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Abstract
Background: Acute lower respiratory tract infection (ALRTI) is often treated in primary care with 
antibiotics. The recent Oral Steroids for Acute Cough (OSAC) randomised controlled trial (RCT) 
showed corticosteroids were not an effective alternative in adults without a diagnosis of asthma with 
ALRTI.
Aim: To investigate if corticosteroids are beneficial for ALRTI in patients with unrecognised asthma.
Design & setting: An exploratory analysis was undertaken of the primary care OSAC trial.
Method: A subgroup analysis was performed in patients who responded ‘yes’ to the following 
International Primary Care Airways Group (IPCAG) question: did you have wheeze and/or at least two 
of nocturnal cough or chest tightness or dyspnoea in the past year. Sensitivity analyses were carried 
out on those who answered ‘yes’ to wheeze and at least two of the nocturnal symptoms. The primary 
outcomes were as follows: duration of cough (0–28 days, minimum clinically important difference 
[MCID] of 3.79 days) and mean symptom severity score (range 0–6; MCID 1.66 units).
Results: In total, 40 (10%) patients were included in the main analysis: mean age 49 years (standard 
deviation [SD] = 17.9), 52% male. Median cough duration was 3 days in both prednisolone (interquartile 
range [IQR] = 2–6 days) and placebo (IQR = 1–6 days) groups (adjusted hazard ratio [HR] = 1.10; 95% 
confidence interval [CI] = 0.47 to 2.54; P = 0.83), equating to 0.24 days longer in the prednisolone 
group (95% CI = 1.23 days shorter to 2.88 days longer). Mean symptom severity difference was –0.14 
(95% CI = –0.78 to 0.49; P=0.65) comparing prednisolone with placebo. Similar findings were found 
in the sensitivity analysis.
Conclusion: No evidence was found to support the use of corticosteroids for ALRTI in patients 
with clinically unrecognised asthma. Clinicians should not use the IPCAG questions to target oral 
corticosteroid treatment in patients with ALRTI.
Hawkey S et al. BJGP Open 2020; DOI: 10.3399/bjgpopen20X101099
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How this fits in
Corticosteroids are an increasingly used alternative to antibiotics for ALRTI in some countries. The 
recently published OSAC randomised trial was the first to investigate the effectiveness of oral steroids 
in adults without a diagnosis of asthma with ALRTI, and found no evidence to support their use. This 
exploratory analysis was conducted to see if participants with unrecognised asthma (at the time of 
randomisation) experienced a better response to oral corticosteroids than the remainder of the study 
sample (those who did not have unrecognised asthma). This study shows they did not. If they had, it 
would have been important for two reasons. First, primary care clinicians might have wished to use 
the British Thoracic Society (BTS) approved questionnaire (used to identify those with unrecognised 
asthma) to identify those who would benefit the most, and second, it would have provided an 
important ‘signal’ that the research community might have wished to confirm in future research. In 
the meantime, clinicians should not use the IPCAG questions to target oral corticosteroid treatment 
in patients with ALRTI.
Introduction
ALRTI is one of the most common conditions seen in primary care,1–3 accounting for 60% of antibiotic 
prescribing in general practice2 and costing the NHS an estimated 190 million GBP each year.4 This 
not only places a significant financial burden on the NHS, but also contributes to the worldwide 
problem of emerging antimicrobial resistance.
There is evidence to suggest the effectiveness of antibiotics in ALRTI is limited. A European trial of 
amoxicillin found that when pneumonia was not suspected, antibiotics did not alter symptom duration 
or severity.5 This was also the case for those deemed at high risk; that is, smokers, and those with 
green sputum, fever, abnormal lung signs, or known lung disease.6 Similar findings were reported in a 
Cochrane review of nine trials including >750 patients with acute bronchitis.7
There is considerable overlap between ALRTI and acute asthma. Both conditions can present 
with obstructive symptoms associated with reduced forced expiratory volume (FEV).8,9 At a cellular 
level, ALRTI and asthma both cause airway inflammation and transient airway hyper- responsiveness.8,9 
Although corticosteroids are the mainstay of treatment in asthma,10 and are reported to be effective 
for community- acquired pneumonia treated in hospital,11 there has been an absence of evidence for 
ALRTI in primary care. A systematic review investigating inhaled corticosteroids found insufficient 
evidence to recommend their use,12 and the recently conducted OSAC randomised trial found that 
oral corticosteroids did not reduce the duration of moderately bad or worse cough, or symptom 
severity in adults without a diagnosis of asthma with ALRTI.13
However, corticosteroids could be more beneficial in those who have unrecognised asthma, or are 
at risk of developing asthma. Asthma is both underdiagnosed and under- reported, particularly in adult 
and older populations.14–18 A Danish study found 67% of an ‘asthmatic cohort’ (defined by respiratory 
symptoms and airway hyper- responsiveness to methacholine, peak flow variability >20% or ≥500 ml 
increase in FEV1 after bronchodilator challenge) did not have a formal diagnosis of asthma in their 
medical records,14 with similar results seen in a Dutch15 and an Australian study.16
Given the theoretical benefit of oral corticosteroids in people with asthma presenting with ALRTI 
and the underdiagnosis of asthma in the general population, this exploratory analysis of the OSAC 
trial sought to investigate whether oral corticosteroids reduced the severity and duration of symptoms 
in a subgroup of patients with clinically unrecognised asthma. If shown to be the case, further research 
would need to replicate the finding, which could then inform the selection of patients with ALRTI most 
likely to benefit from oral corticosteroids.
Method
Summary of the OSAC trial
The study details are reported fully in the original OSAC article.13 To summarise, participants were 
recruited from 54 GP practices between July 2013 and October 2014. Patients were eligible if aged 
≥18 years, presenting with an acute (≤28 days) cough with at least one lower respiratory tract infection 
(LRTI) symptom — phlegm, chest pain, wheezing, or shortness of breath — in the last 24 hours, and 
not requiring immediate antibiotics. Patients were excluded if they had: chronic pulmonary disease; 
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Table 1 Baseline characteristics (main analysis groups)
Characteristics, n (%)a
Main analysis group (N = 40)








Bristol 15 (68.2) 11 (61.1) 205 (57.3)
Oxford 3 (13.6) 3 (16.7) 78 (21.8)
Southampton 3 (13.6) 1 (5.6) 41 (11.5)
Nottingham 1 (4.5) 3 (16.7) 34 (9.5)
Demographics and past medical history
Sex, male 13 (59.1) 8 (44.4) 127 (35.5)
Mean age, years (SD) 53.02 (18.1) 43.7 (16.6) 47.2 (15.8)
Median weight, kg (IQR)b 78.0 (64.0–95.0) 80.5 (70.0–94.0) 76 (65.0–90.0)
Median height, cm (IQR)c 172.5 (162.0–176.0) 171.5 (166.0–175.0) 168 (162.0–
175.0)
Ethnic group, Whitec 22 (100) 16 (88.9) 343 (96.1)
Occupation
Employed 14 (63.6) 10 (55.6) 256 (71.5)
Unemployed 3 (13.6) 2 (11.1) 13 (3.6)
Retired 4 (18.2) 5 (27.8) 62 (17.3)
Other 1 (4.5) 1 (5.5) 27 (7.5)
Median deprivation score (IQR)d 18.5 (7.0–28.0) 12.5 (10.0–24.5) 11 (5.0–22.0)
Smoking statusc
Current 6 (27.3) 4 (22.2) 59 (16.5)
Past 6 (27.3) 10 (55.6) 102 (28.6)
Never 10 (45.5) 4 (22.2) 196 (54.9)
Lives with smokere 3 (15.0) 6 (35.3) 48 (14.1)
Received asthma medication >5 years previouslyf 1 (5.0) 2 (11.1) 15 (4.4)
Personal history of hay feverg 6 (31.6) 5 (29.4) 76 (22.3)
Personal history of eczemah 2 (10.5) 4 (22.2) 50 (14.8)
Family history asthma or hay fever or eczemai 9 (45.0) 11 (61.1) 129 (38.7)
Influenza vaccine in last 12 months 6 (27.3) 4 (22.2) 97 (27.1)
Recruited in winter (1 October–31 March) 14 (63.6) 13 (72.2) 199 (55.6)
Clinical characteristics and management
Median prior duration of cough, days (IQR) 12.0 (7.0–21.0) 14.0 (6.0–21.0) 11.0 (6.0–19.0)
Sputum, symptom <24 hourc 15 (68.2) 16 (88.9) 274 (76.8)
Shortness of breath, symptom <24 hour 15 (68.2) 12 (66.7) 252 (70.4)
Wheeze, symptom <24 hourc 13 (59.1) 9 (50.0) 164 (45.9)
Chest pain, symptom <24 hour 11 (50.0) 7 (38.9) 167 (46.6)
Median patient- reported illness severity (0–10), 
(IQR)j
6.5 (3.0–7.0) 5.0 (4.0–6.0) 6.0 (4.0–7.0)
Mean pulse rate, bpm (SD) 72.9 (13.0) 76.4 (10.6) 78.1 (12.0)
Mean temperature, °C (SD) 36.6 (0.4) 36.6 (0.5) 36.6 (0.5)
continued on next page
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received any asthma medication in the past 5 years; met the National Institute for Health and Care 
Excellence (NICE) criteria for severe infection or complications;2 required same- day hospital admission; 
or required same- day antibiotics.
Participants were asked to take two tablets daily for 5 days (prednisolone 20 mg or placebo), starting 
on the day of consultation, reflecting the dose and duration used in acute asthma. Randomisation was 
concealed and recruiting clinicians, participants, and trial team members were masked to treatment 
allocation until data analyses were complete. Participants were asked to report the presence and 
severity of symptoms using a validated19 diary used in previous trials.4,5 Symptoms were measured 
using a zero to six scale, shown to be sensitive to change,4 from zero (no problem) to three (moderately 
bad) and up to six (as bad as it could be). All symptoms were measured daily, with twice daily peak 
expiratory flow, for 28 days or until symptom resolution.
Defining clinically unrecognised asthma
Patients were identified as having clinically unrecognised asthma based on answers to the IPCAG 
questionnaire (see Supplementary Box S1).20 This was developed to estimate the population prevalence 
of asthma, and includes symptoms with the strongest evidence of their value in diagnosing for asthma 
(wheeze, nocturnal cough or chest tightness or dyspnoea, dyspnoea on exertion, dyspnoea at rest).10 
The version used in OSAC (see Supplementary Box S2) specified that participants must ‘think about 
the presence of symptoms in the 12 months before their current illness started'.
The BTS and Scottish Intercollegiate Guidelines Network (SIGN) guidelines state that isolated 
symptoms are neither sensitive nor specific for asthma, with symptom combinations more useful.10 The 
presence of wheeze and/or at least two out of three nocturnal symptoms (dyspnoea, chest tightness, 
and cough) were used for the main analyses as this has been shown to be 80.0% sensitive and 85.9% 
specific.21 In case the main analysis definition was too sensitive, a sensitivity analysis was conducted 
using a more specific definition, including patients who answered ‘yes’ to the presence of wheeze and 
at least two out of the three nocturnal symptoms. Based on asthma prevalence from  asthma. org. uk,22 
Characteristics, n (%)a
Main analysis group (N = 40)







Mean oxygen saturation, % (SD)c 97.6 (1.8) 97.8 (0.9) 97.7 (1.2)
Baseline abnormal peak flowc 11 (50.0) 5 (27.8) 150 (42.0)
Abnormal respiratory rate 0 (0) 0 (0) 3 (0.8)
Chest recession or prolonged expiration 0 (0) 0 (0) 1 (0.3)
Wheeze or rhonchi, auscultation 2 (9.1) 2 (11.1) 18 (5.0)
Crackles or crepitations, auscultationh 2 (9.1) 0 (0) 8 (2.2)
Bronchial breathing 0 (0) 1 (5.6) 1 (0.3)
Taken prescribed β agonist in past 24 hours 2 (9.1) 1 (5.6) 9 (2.5)
Over- the- counter drugs taken for current cough 12 (54.5) 12 (66.7) 243 (67.9)
Given delayed antibiotic script 4 (18.2) 3 (16.7) 40 (11.2)
aUnless otherwise stated. bWeight missing for 2 in the rest of the OSAC sample. cHeight, ethnicity, smoking status, 
sputum, wheeze, oxygen saturation, and abnormal peak flow data missing for one in the rest of OSAC sample. 
dEnglish Index of Multiple Deprivation scores (range 0–100; higher scores indicate higher levels of deprivation). 
Data missing for two in placebo group and seven in the rest of OSAC sample. eLiving with smoker data missing 
for two in the prednisolone group, one in the placebo group and seventeen in the rest of OSAC sample. fData 
on use of asthma medication >5 years previously missing for two patients in the prednisolone group and fifteen 
in the rest of OSAC sample. gPersonal history of hay fever data missing for three in the prednisolone group, one 
in the placebo group and seventeen in the rest of OSAC sample. hPersonal history of eczema data missing for 
three in the prednisolone group and twenty one in the rest of OSAC sample. iFamily history of hay fever, eczema, 
or asthma data missing for two in the prednisolone group and twenty five in the rest of OSAC sample. jPatient- 
reported illness severity scores: 0 (completely well) to 10 (extremely unwell). Missing for one in the rest of OSAC 
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NHS datasets,23 and the Quality and Outcomes Framework (QoF)24 it was anticipated 5%–17% of the 
OSAC cohort would have clinically unrecognised asthma.
Outcomes and statistical methods
The same pre- defined outcomes from the OSAC trial were used.13 The first of two primary outcomes 
was duration of moderately bad or worse cough, defined as the number of days from randomisation 
to the last day the cough was scored ≥3, prior to at least two consecutive days scored <3, up to a 
maximum of 28 days. The second was the mean of the six symptom (cough, phlegm, shortness of 
breath, sleep disturbance, feeling generally unwell, and activity disturbance) severity scores on days 
2–4. As this was an exploratory analysis, the sample size was predetermined by the MCID in both 
outcomes from the original study;13 3.79 days for duration of cough and 1.66 units for symptom 
severity.
All analyses were carried out in Stata (version 15.1). Main comparative and sensitivity analyses 
were conducted as per the OSAC trial to allow comparison with the original study, adjusting for 
the relevant baseline measure (either prior cough duration or patient- reported illness severity) and 
centre. Semi- parametric Cox- proportional hazard models were used to analyse the duration of 
moderately bad or worse cough. HRs were reported comparing instantaneous rate of resolution of 
cough between prednisolone and placebo groups. Parametric Weibull accelerated failure time (AFT) 
models were used to present time ratios. Mean symptom severity score from days 2–4 was analysed 
using linear regression models. Secondary additional adjustment was performed where appropriate, 
accounting for factors demonstrating imbalance at baseline. These were defined prior to the analysis 
as a difference of >15% for binary and >0.5 SDs for continuous outcomes; a conservative approach to 
accommodate for the small sample size. Smoking was also adjusted for, a likely confounding factor, 
given its link with both asthma and cough.25 To test whether the treatment effect differed in the 
defined subgroups, compared with the rest of the OSAC cohort, interactions were included, which 
Table 2 Primary outcomes (main analysis groups)
Prednisolone Placebo Prednisolone versus placebo
n Median (IQR) n Median (IQR)
HR (95% CI);
P value
Time ratioa (95% 
CI); P value
Duration of moderately 
bad or worse cough
17 3 (2–6) 14 3 (1–6)
Unadjusted 1.01 (0.49 to 2.05); 
P = 0.99
1.03 (0.53 to 2.02); 
P = 0.94
Adjusted for centre and 
baseline cough durationb
1.10 (0.47 to 2.54); 
P = 0.83




1.19 (0.39 to 3.75); 
P = 0.75
0.77 (0.38 to 1.57); 
P = 0.47
n Mean (SD) n Mean (SD) Difference in means (95% CI); P value
Mean symptom severity 
score, days 2–4d
21 1.83 (1.05) 16 1.95 (0.87)
Unadjusted –0.13 (–0.79 to 0.53); P = 0.69
Adjusted for centre and 
baseline illness severity
–0.14 (–0.78 to 0.49); P = 0.65
Secondary additional 
adjustment 0.02 (–1.01 to 1.07); P = 0.95
aTime ratio can be interpreted as the relative increase or decrease in time to resolution from moderately bad 
or worse cough in the prednisolone versus the placebo group. bBaseline measure of duration of cough is prior 
duration of cough (1–28 days) and of mean symptoms severity score is patient- reported illness severity (range 
0–10). cAdjusted for centre, baseline cough duration or illness severity, factors showing imbalance at baseline 
(age, family history of atopy, smoking status, lives with smoker, sputum, and abnormal peak flow). dSee Method 
section for derivation of mean symptoms severity score (0 [least severe] to 6 [most severe]). HR = hazard ratio. IQR 
= interquartile range. SD = standard deviation.
Hawkey S et al. BJGP Open 2020; DOI: 10.3399/bjgpopen20X101099
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were followed by a likelihood ratio test. See Appendix S1 for details of the secondary outcomes and 
analyses.
Results
Study population and outcome data completeness
In total, 40 (10%) of the 398 patients randomised in the OSAC study met the symptom criteria for the 
main analysis (wheeze and/or at least two of nocturnal wheeze or cough or dyspnoea), and 21 (5%) 
met the criteria for the sensitivity analysis (wheeze and at least two of nocturnal wheeze or cough or 
dyspnoea).
Main analysis group participants had a mean age of 49 (SD = 17.9) years; 52% were male; 25% 
were current smokers; 78% reported phlegm; 68% shortness of breath; 55% wheezing; and 40% 
had abnormal peak flow. Baseline characteristics were similar between prednisolone and placebo 
arms. However, in the prednisolone group, a higher percentage of participants were older, lived 
with a smoker, reported phlegm, and had an abnormal peak flow than the placebo group (Table 1). 
Conversely, a lower percentage had a family history of atopy than the placebo group. Compared with 
the rest of the OSAC cohort, a higher percentage of patients were current smokers and had a family 
history of atopy.
Figure 1 Kaplan–Meier analysis of time to recovery from moderately bad or worse cough (main analysis groups)
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For duration of moderately bad or worse cough, data were available for 31 (78%) participants in the 
main analysis group. Six were not included as they reported an initial cough severity of <3 points (that 
is, not moderately bad or worse), two withdrew, and one was lost to follow- up. For symptom severity, 
data were available for 37 (92%) participants.
Primary outcomes
Moderately bad or worse cough
In the main analysis group, the median duration of moderately bad or worse cough was 3 days for 
both prednisolone (IQR = 2–6 days) and placebo arms (IQR = 1–6 days) (Table  2). Kaplan–Meier 
survival curves showed no clinically important differences between groups (Figure 1). When adjusting 
for centre and baseline cough duration (pre- specified adjustments in the main trial), the Cox model 
found a HR of 1.10 (95% CI = 0.47 to 2.54) comparing prednisolone with placebo, with no clear 
evidence (P = 0.83) of a treatment effect (Table 2). The Weibull AFT model time ratio was 1.08 (95% 
CI = 0.59 to 1.96), showing the time to resolution was 8% (0.24 days) longer (95% CI = 1.23 days 
shorter to 2.88 days longer) with prednisolone compared with placebo (P = 0.79), that is, the 95% 
CI did not include values that exceeded the pre- specified MCID of 3.79 days. Further adjustment for 
factors displaying imbalance at baseline (age, lives with smoker, family history of atopy, sputum, and 
abnormal peak flow) and smoking mildly increased the effect of prednisolone with respect to both the 
models. Although secondary adjustment did alter the time ratio from 1.08 to 0.77, CIs again remained 
within the MCID.
Day 2–4 symptom severity
Mean symptom severity scores (and residuals) were normally distributed, with a mean symptom severity 
of 1.83 (SD = 1.05) and 1.95 (SD = 0.87) for the prednisolone and placebo groups, respectively. When 
adjusting for centre and baseline illness severity, there was a mean symptom severity reduction of 
-0.14 (95% CI = -0.78 to 0.49; P = 0.65) between prednisolone and placebo; that is, the 95% CI did 
not include values that exceeded the MCID of 1.66. Secondary additional adjustment narrowed the 
difference in the mean symptom severity between groups.
For both primary outcomes, when adding an interaction term for the subgroup, no evidence was 
found to suggest that there were differential treatment effects seen in those who did and did not meet 
the criteria for clinically unrecognised asthma (Figure 2a and b). See Appendix 2, Supplementary 
Table S1, Table S2, and Figure S1 in the supplementary material for the sensitivity analysis results.
Secondary outcomes
In the main analysis group, after adjusting for baseline symptom, prednisolone had no distinguishable 
effect on any ALRTI symptoms or duration of abnormal peak flow up to 28 days, or cough up to 56 
days (Table 3). There was also no effect on antibiotic use, the proportion of participants stateing 
they felt better or would use the same medication for similar illnesses in the future or the number of 
adverse events. Three of the patients in the OSAC trial went on to receive an asthma diagnosis, of 




This exploratory analysis of the OSAC trial provides evidence that a moderate- dose oral prednisolone 
does not reduce the duration of moderately bad or worse cough, or symptom severity at days 2–4 in 
patients presenting to primary care with ALRTI with probable clinically unrecognised asthma.
Strengths and limitations
The main strength is that, to the authors' knowledge, this is the first time a rigorously conducted, 
randomised controlled trial has been used to explore the role of corticosteroids for patients with ALRTI 
and previously unrecognised asthma. A limitation was that the original OSAC study excluded patients 
who received asthma medication in the last 5 years, meaning it was not possible to include patients 
Hawkey S et al. BJGP Open 2020; DOI: 10.3399/bjgpopen20X101099
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Figure 2 Forest plots of the subgroups for a) duration of moderately bad or worse cough and b) mean symptom severity score. HR = hazard ratio. 
OSAC = Oral Steroids for Acute Cough
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Mean AUC (SD) Difference in mean AUC
(95% CI); P value
Cough 36.29 (25.89) 34.38 (24.71)
Unadjusted 1.91 (–15.20 to 19.01); P = 0.82
Adjusted for baselinea 2.27 (–15.22 to 19.75); P = 0.79
Phlegm 20.60 (19.97) 30.69 (25.42)
Unadjusted –10.09 (–25.23 to 5.04); P = 0.19
Adjusted for baselineb –10.35 (–26.18 to 5.48); P = 0.19
Shortness of breath 12.45 (16.13) 17.56 (19.79)
Unadjusted –5.11 (–17.10 to 6.88); P = 0.39
Adjusted for baselineb –3.64 (–15.56 to 8.29); P = 0.54
Wheeze 15.12 (16.4) 16.13 (18.93)
Unadjusted –1.01 (–12.82 to 10.80); P = 0.86
Adjusted for baselineb –2.10 (–13.75 to 9.54); P = 0.72
Blocked or runny nose 15.67 (20.78) 20.15 (25.66)
Unadjusted –4.49 (–19.99 to 11.00); P = 0.56
Adjusted for baselineb –4.24 (–19.83 to 11.34); P = 0.58
Chest pain 10.33 (14.50) 5.91 (8.52)
Unadjusted 4.43 (–3.85 to 12.71); P = 0.29
Adjusted for baselineb 5.07 (–2.74 to 12.88); P = 0.17
Fever 3.48 (6.36) 5.53 (14.08)
Unadjusted –2.06 (–9.06 to 4.95); P = 0.56
Adjusted for baselineb –2.91 (–9.25 to 3.43); P = 0.36
Muscle ache 13.74 (24.87) 8.31 (14.46)
Unadjusted 5.43 (–8.75 to 19.60); P = 0.44
Adjusted for baselineb 5.84 (–8.45 to 20.13); P = 0.41
Headache 11.64 (24.67) 6.88 (15.84)
Unadjusted 4.77 (–9.61 to 19.14); P = 0.51
Adjusted for baselineb 4.91 (–9.54 to 19.36); P = 0.50
Sleep disturbance 20.29 (24.84) 17.94 (24.07)
Unadjusted 2.35 (–14.17 to 18.86); P = 0.78
Adjusted for baselineb 3.23 (–13.67 to 20.12); P = 0.70
Feeling unwell 19.86 (27.79) 17.19 (22.54)
Unadjusted 2.67 (–14.62 to 19.96); P = 0.76
Adjusted for baselineb 1.29 (–15.35 to 17.93); P = 0.88
Activity disturbance 10.14 (13.16) 10.59 (20.64)
Unadjusted –0.45 (–11.75 to 10.85); P = 0.94
Adjusted for baselineb –0.15 (–11.56 to 11.27); P = 0.98
Median duration (IQR) HR (95% CI); P value
continued on next page
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Duration of moderate- bad 
or worse cough (censored 
at 56 days)c
3 (2–6) 3 (1–6)
Unadjusted 1.01 (0.50 to 2.05); P = 0.99
Adjusted for baselineb 1.01 (0.49 to 2.04); P = 0.99
Duration of any cough 
(censored at 56 days)c
18 (14–31) 13 (6–26)
Unadjusted 0.68 (0.32 to 1.46); P = 0.32
Adjusted for baselineb 0.69 (0.32 to 1.48); P = 0.35
Duration of abnormal 
peak flowc
24 (4–n/a)d 6 (4–n/a)d
Unadjusted 0.45 (0.17 to 1.24); P = 0.12
Adjusted for baselinea 0.51 (0.18 to 1.42); P = 0.21
Adjusted for baselinee 0.79 (0.22 to 2.79); P = 0.71
n (%) OR (95% CI); P value
Consumption of antibiotics 
up to 7 days
1 (4.8) 1 (6.3)
Unadjusted 0.75 (0.04 to 12.99); P = 0.84
Adjusted for delayed script 0.74 (0.04 to 13.48); P = 0.84
Consumption of antibiotics 
up to 28 daysf
2 (16.7) 3 (33.3)
Unadjusted 0.46 (0.07 to 3.12); P = 0.42
Adjusted for delayed script 0.38 (0.04 to 3.27); P = 0.38
Participant agrees trial 
tablets helped them feel 
betterf
6 (33.3) 6 (40.0)
Unadjusted 0.75 (0.18 to 3.11); P= 0.69
Participant agrees they 
would take trial tablets in 
futuref
9 (50.0) 9 (60.0)











Unadjusted 1.31 (0.31 to 5.62); P = 0.72g
Adjusted for baselineh 1.17 (0.25 to 5.38); P = 0.84g
aAdjusted for prior duration of cough in days. bAdjusted for presence of symptom at baseline (including previous 
24 hours). cAnalysis of duration of moderately bad or worse cough (56 days) includes 17 in the prednisolone 
and 14 in the placebo group (participants without moderately bad or worse cough on day 1 excluded); analysis 
of duration of any cough (56 days) includes 21 in the prednisolone group and 16 in the placebo group; and 
analysis of duration of abnormal peak flow includes 11 in the prednisolone group and 13 in the placebo group 
(participants with normal peak flow on day 1 excluded). dA large proportion of participants still had abnormal 
peak flow at 28 days – a 75th percentile could therefore not be calculated. eAdjusted for baseline cough duration 
and baseline abnormal peak flow. fAntibiotic analysis includes 12 in the prednisolone and 9 in the placebo group 
up to 28 days; patient satisfaction analysis includes 18 in the prednisolone group ad 15 in the placebo group. 
gOrdinal logistic regression; adverse event data available for 22 in the prednisolone group and 18 in the placebo 
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with recognised asthma. It is, however, an underdiagnosed condition in adults and older people.14–18 
Furthermore, the pre- determined definition used to identify unrecognised patients with asthma in this 
analysis was formulated using strict criteria, using BTS guidelines, and symptom combinations with 
high sensitivity or specificity for asthma.10,21
As the OSAC study questionnaire stated that ‘patients must think about symptoms in the 12 
months before their current illness started’,13 it is possible that a minority may have misinterpreted 
this question and included symptoms related to their current ALRTI, resulting in a higher number of 
patients meeting the criteria for clinically unrecognised asthma. The use of a questionnaire and self- 
reported outcomes is, in itself, a limitation of the OSAC trial as a whole.
Given that the definition for clinically unrecognised asthma needed to be stringent (while also 
replicating asthma prevalence in the general population); it was recognised that only a small proportion 
of the OSAC cohort could be included. Consequently, baseline characteristics were imbalanced; 
although, additional adjustments were made to account for this. However, despite the relatively low 
number of patients included in the main analyses, the 95% CIs did not include the pre- specified 
MCIDs for both primary outcomes.
Comparison with existing literature
These findings are consistent with the original OSAC trial,13 which to the authors’ knowledge is the 
only study to investigate the benefit of oral corticosteroids in ALRTI. The findings also replicate other 
studies that have found little benefit from oral or intranasal steroids in acute rhinosinusitis,26,27 but 
contrast with recent meta- analyses demonstrating clinical benefits for sore throat in primary care and 
community- acquired pneumonia treated in hospital.11,28 In the current analysis, the median duration of 
cough in both placebo and prednisolone groups was 3 days, which was shorter than 5 days observed 
for both arms in the original OSAC trial. Mean symptom severity scores were also lower in this subset 
compared with the whole OSAC cohort (1.83 versus 1.99 for prednisolone; 1.95 versus 2.16 for 
placebo). This was unexpected given that ALRTIs are reported to be more severe and prolonged in 
people with asthma,7,8 and may be owing to chance or patient selection.
Implications for research and practice
The main reason for conducting this analysis was to see if participants with unrecognised asthma 
experienced a better response to oral corticosteroids than the remainder of the study sample. This 
analysis, although underpowered, found no evidence to suggest that they did. If they had, it would 
have been important for two reasons. First, primary care clinicians might have wished to use the 
questionnaire (used to identify those with unrecognised asthma) to identify those who would benefit 
the most, and second, it would have provided an important ‘signal’ that the research community 
might have wished to confirm in future research.
No evidence was found to support the use of corticosteroids for ALRTI in patients with clinically 
unrecognised asthma. Clinicians should not use the IPCAG questions to target oral corticosteroid 
treatment in patients with ALRTI.
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